Cost-Effectiveness of the Addition of Bevacizumab to First-Line Chemotherapy With Carboplatin and Paclitaxel in Patients With Non–Small Cell Lung Cancer (NSCLC)

Publication date: December 2020Source: Value in Health Regional Issues, Volume 23Author(s): Elizabeth Parody-Rúa, Cesar Augusto Guevara-Cuellar
Source: Value in Health Regional Issues - Category: International Medicine & Public Health Source Type: research